KPF
SPRY icon

K2 Principal Fund’s ARS Pharmaceuticals SPRY Stock Holding History

K2 Principal Fund’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-264,400
Closed -$1.77M – 268
2023
Q2 		$1.77M Buy
264,400
+152,800
+137% +$1.02M 0.41% 59
2023
Q1 		$727K Buy
+111,600
New +$857K 0.1% 136

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tyro Capital Management Miami, Florida $446M AUM 84.15% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

K2 Principal Fund's SPRY Position: Q2 2026 in Review

K2 Principal Fund reduced its ARS Pharmaceuticals (SPRY) stake by 33% in Q2 2026, selling an estimated $1.59M and leaving 375,132 shares worth $3M. The position accounts for 0.22% of the portfolio, ranked #128.

K2 Principal Fund first reported a position in SPRY in Q2 2022 and has held it in 16 quarters since. The position peaked at $24.5M in Q4 2022. 209 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • K2 Principal Fund held 375,132 shares of ARS Pharmaceuticals worth $3M as of Q2 2026.
  • K2 Principal Fund sold 184,565 ARS Pharmaceuticals shares in Q2 2026, an estimated $1.59M.
  • ARS Pharmaceuticals made up 0.22% of K2 Principal Fund's portfolio in Q2 2026, its #128 holding.
  • K2 Principal Fund first reported a position in ARS Pharmaceuticals in Q2 2022 and has held it in 16 quarters since.
  • K2 Principal Fund's ARS Pharmaceuticals position peaked at $24.5M in Q4 2022.
  • 209 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on K2 Principal Fund's 13F filing for Q2 2026, filed 7 Aug 2026.